300233.SZ
金城医药
SZSE · Basic Materials · C 制造业 · CN
CNY 13.07
−5.08%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.8B | 2.7B | 3.4B | 3.5B | 3.5B |
| Cost of Revenue | 1.8B | 1.8B | 2.0B | 2.0B | 1.9B |
| Gross Profit | 999.3M | 986.3M | 1.4B | 1.5B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 193.6M | 188.5M | 170.3M | 184.7M | 171.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 327.3M | 339.0M | 378.5M | 390.8M | 400.7M |
| Selling & Marketing Expense | 287.0M | 308.7M | 496.4M | 680.6M | 628.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 857.1M | 879.0M | 1.1B | 1.3B | 1.2B |
| Cost and Expenses | 2.6B | 2.6B | 3.1B | 3.3B | 3.1B |
| Operating Income (EBIT) | 111.1M | 84.2M | 267.1M | 225.8M | 353.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 104.4M | 78.0M | 268.4M | 225.4M | 346.0M |
| Income Tax Expense | 39.4M | 35.7M | 60.7M | 32.1M | 60.1M |
| Bottom Line | |||||
| Net Income | 66.9M | 44.2M | 196.8M | 174.7M | 273.4M |
| Earnings from Cont. Ops | 65.0M | 42.3M | 207.7M | 193.3M | 285.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 66.9M | 44.2M | 196.8M | 174.7M | 273.4M |
| Per Share | |||||
| Basic EPS | CN¥0.18 | CN¥0.12 | CN¥0.52 | CN¥0.45 | CN¥0.71 |
| Diluted EPS | CN¥0.18 | CN¥0.12 | CN¥0.52 | CN¥0.45 | CN¥0.71 |
| Revenue Per Share | CN¥7.18 | CN¥7.43 | CN¥8.91 | CN¥9.11 | CN¥9.11 |
| Shares | |||||
| Basic Shares Outstanding | 385.3M | 368.2M | 378.4M | 388.2M | 385.0M |
| Diluted Shares Outstanding | 385.3M | 368.2M | 378.4M | 388.2M | 385.0M |
| Profitability Metrics | |||||
| EBITDA | — | 406.4M | 587.5M | 534.8M | 608.1M |
| D&A | — | 322.2M | 320.3M | 309.0M | 254.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026